| Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria CH Polman, SC Reingold, B Banwell, M Clanet, JA Cohen, M Filippi, ... Annals of neurology 69 (2), 292-302, 2011 | 10940 | 2011 |
| Defining the clinical course of multiple sclerosis: the 2013 revisions FD Lublin, SC Reingold, JA Cohen, GR Cutter, PS Sørensen, ... Neurology 83 (3), 278-286, 2014 | 3769 | 2014 |
| Natalizumab plus interferon beta-1a for relapsing multiple sclerosis RA Rudick, WH Stuart, PA Calabresi, C Confavreux, SL Galetta, ... New England Journal of Medicine 354 (9), 911-923, 2006 | 1706 | 2006 |
| ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis X Montalban, R Gold, AJ Thompson, S Otero-Romero, MP Amato, ... Multiple Sclerosis Journal 24 (2), 96-120, 2018 | 922 | 2018 |
| Natural history of multiple sclerosis with childhood onset C Renoux, S Vukusic, Y Mikaeloff, G Edan, M Clanet, B Dubois, ... New England Journal of Medicine 356 (25), 2603-2613, 2007 | 723 | 2007 |
| Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled … L Kappos, G Comi, H Panitch, J Oger, J Antel, P Conlon, L Steinman, ... Nature medicine 6 (10), 1176-1182, 2000 | 608 | 2000 |
| EFNS guidelines on diagnosis and management of neuromyelitis optica J Sellner, M Boggild, M Clanet, RQ Hintzen, Z Illes, X Montalban, ... European journal of neurology 17 (8), 1019-1032, 2010 | 606 | 2010 |
| Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. G Edan, D Miller, M Clanet, C Confavreux, O Lyon-Caen, C Lubetzki, ... Journal of Neurology, Neurosurgery & Psychiatry 62 (2), 112-118, 1997 | 584 | 1997 |
| Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations F Bergametti, C Denier, P Labauge, M Arnoult, S Boetto, M Clanet, ... The American Journal of Human Genetics 76 (1), 42-51, 2005 | 511 | 2005 |
| Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study B Stankoff, E Waubant, C Confavreux, G Edan, M Debouverie, ... Neurology 64 (7), 1139-1143, 2005 | 379* | 2005 |
| Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring L Kappos, D Bates, G Edan, M Eraksoy, A Garcia-Merino, N Grigoriadis, ... The Lancet Neurology 10 (8), 745-758, 2011 | 374 | 2011 |
| A double-blind, placebo-controlled randomized clinical trial of α-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis C Desnuelle, M Dib, C Garrel, A Favier Amyotrophic Lateral Sclerosis and other motor neuron disorders 2 (1), 9-18, 2001 | 347 | 2001 |
| MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: a randomised, double-blind, placebo-controlled study A Tourbah, C Lebrun-Frenay, G Edan, M Clanet, C Papeix, S Vukusic, ... Multiple Sclerosis Journal 22 (13), 1719-1731, 2016 | 343 | 2016 |
| Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia calcification G Nicolas, C Pottier, D Maltête, S Coutant, A Rovelet-Lecrux, S Legallic, ... Neurology 80 (2), 181-187, 2013 | 296 | 2013 |
| A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS M Clanet, EW Radue, L Kappos, HP Hartung, R Hohlfeld, ... Neurology 59 (10), 1507-1517, 2002 | 284 | 2002 |
| Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings AJ Coles, JA Cohen, EJ Fox, G Giovannoni, HP Hartung, E Havrdova, ... Neurology 89 (11), 1117-1126, 2017 | 274 | 2017 |
| Neutralizing antibodies and efficacy of interferon β-1a: a 4-year controlled study L Kappos, M Clanet, M Sandberg-Wollheim, EW Radue, HP Hartung, ... Neurology 65 (1), 40-47, 2005 | 260 | 2005 |
| Neuromyelitis optica in France: a multicenter study of 125 patients N Collongues, R Marignier, H Zephir, C Papeix, F Blanc, C Ritleng, ... Neurology 74 (9), 736-742, 2010 | 259 | 2010 |
| Abnormal ocular movements in Parkinson's disease: evidence for involvement of dopaminergic systems O Rascol, M Clanet, JL Montastruc, M Simonetta, MJ Soulier-Esteve, ... Brain 112 (5), 1193-1214, 1989 | 255 | 1989 |
| Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy E Havrdova, DL Arnold, JA Cohen, HP Hartung, EJ Fox, G Giovannoni, ... Neurology 89 (11), 1107-1116, 2017 | 230 | 2017 |
